117977-18-1

Basic information

• Product Name: 4-(3-Methoxypropoxy)-2,3-dimethylpyridine-N-oxide
• Synonyms: 4-(3-METHOXYPROPOXY)-2,3-DIMETHYLPYRIDINE-N-OXIDE;Pyridine, 4-(3-methoxypropoxy)-2,3-dimethyl-, 1-oxide;4-(3-METHOXYPROPOXY)-2,3-DIMETHYLPYRIDINE 1-OXIDE;4-(3-Methoxypropoxy)-2,3-dimethylPyridineridine N-oxide;4-(3-Methoxypropoxy)-2,3-dimethylpyridin-1-ium-1-olate;4-(3-methoxypropoxy)-2,3-dimethyl-1-oxidopyridin-1-ium
• CAS NO: 117977-18-1
• Molecular Formula: C₁₁H₁₇NO₃
• Molecular Weight: 211.26
• EINECS: 1592732-453-0
• Product Categories: Pyridines;Rabeprazole
• Mol File: 117977-18-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 387.448 °C at 760 mmHg
• Flash Point: 188.122 °C
• Appearance: Light yellow liquid
• Density: 1.058 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.49
• Storage Temp.: Refrigerator, under inert atmosphere
• Solubility: Chloroform (Slightly), Ethyl Acetate (Very Slightly)
• PKA: 2.85±0.10(Predicted)
• CAS DataBase Reference: 4-(3-Methoxypropoxy)-2,3-dimethylpyridine-N-oxide(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3-Methoxypropoxy)-2,3-dimethylpyridine-N-oxide(117977-18-1)
• EPA Substance Registry System: 4-(3-Methoxypropoxy)-2,3-dimethylpyridine-N-oxide(117977-18-1)

Safety Data

• Hazardous Substances Data: 117977-18-1(Hazardous Substances Data)

Usage

Uses

4-(3-Methoxypropoxy)-2,3-dimethylpyridin-1-ium-1-olate?is used in preparation of Picolylsulfides and related drugs by using Esterification and Thioetherification as the key steps.

InChI:InChI=1/C11H17NO3/c1-9-10(2)12(13)6-5-11(9)15-8-4-7-14-3/h5-6H,4,7-8H2,1-3H3

Upstream product

• 1589-49-7 methoxypropanol 
• 37699-43-7 2,3-dimethyl-4-nitropyridine N-oxide 
• 59886-90-7 4-chloro-2,3-dimethylpyridine-N-oxide 

Downstream Products

• 675198-19-3 [4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methanol hydrochloride 
• 117977-21-6 rabeprazole sulfide 
• 118175-10-3 2-hydroxymethyl-4-(3-methoxy propoxy)-3-methyl pyridine 
• 117977-20-5 2-chloromethyl-4-(3-methoxy propyloxy)-3-methyl pyridine 

Relevant articles and documents

Development of a scalable and safe process for the production of 4-chloro-2,3-dimethylpyridine- N -oxide as a key intermediate in the syntheses of proton pump inhibitors

2-(Pyridin-2-ylmethanesulfinyl)-1H-benzimidazole-based drugs belong to the most prominent and successfully applied proton pump inhibitors. To fulfill the demand for a flexible and safe procedure for the synthesis of early-stage intermediates which are known to possess a strong exothermal decomposition potential, we have developed a high-yielding telescoped procedure for the synthesis of a key intermediate in the synthesis of these drugs. This strategy turned out to be highly reproducible in laboratory as well as on pilot-plant scale. As the starting material, as well as some of the intermediates, shows a highly exothermal decomposition potential, extensive safety investigations were undertaken. The whole process was adapted in a safe and reliable manner based on the outcome of this systematic approach. Considering these precautions, no safety issues were observed, neither in the laboratory nor in the pilot plant.

Diversified synthesis of novel quinoline and dibenzo thiazepine derivatives using known active intermediates

The novel drug development to control resisting infections in conventional drug therapy is a need of today. Few antiulcer relative derivatives developed by approaching convergent synthesis. The derivatives synthesized successfully are dibenzo thiazepine-pyridine (SLN11-SLN15) and benzimidazole-hydroquinoline based derivatives (SLN16-SLN20). It involved the coupling through microwave, sonication and conventional techniques at final step. The efficient technology identified as sonication technique basically time and yield. The reported compounds were structural characterized by elemental analysis and spectral studies such as 1H, 13C NMR and MS.

NEW PRAZOLE COMPOUND AND THE USE THEREOF

The present invention relates to derivatives of compounds (formula (I) or (II)) and their salts, wherein R1 represents lower alkyl or the lower alkyl substituted by halogen atoms, R2 represents straight-chain or branched-chain alkyl containing 1-4 carbon atoms and R3 represents hydrogen atom or alkali metals such as lithium, sodium, potassium or alkaline-earth metals such as magnesium and calcium. In the present invention, compounds with formula (I) or (II) and their derivatives or salts thereof acceptable in pharmacy and pharmacology can remarkably improve the effectiveness of anti-ulcer in alimentary tract, weakly inhibit gastric acid secretion, reduce the risk of stomach cancer and have excellent bio-availability and other in-vive pharmacokinetic characteristics.